Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Neurosense Therapeutics Ltd (NRSN)

Neurosense Therapeutics Ltd (NRSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,794
  • Shares Outstanding, K 10,944
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,041 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NRSN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7500 +8.57%
on 07/25/22
2.7000 -29.63%
on 07/12/22
-0.7800 (-29.10%)
since 07/08/22
3-Month
1.2300 +54.47%
on 05/12/22
4.4700 -57.49%
on 06/30/22
+0.5500 (+40.74%)
since 05/10/22

Most Recent Stories

More News
NeuroSense Therapeutics CEO Provides Key Corporate Update Video

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

NRSN : 1.9000 (+1.60%)
SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive...

CHMA : 3.76 (-6.00%)
NRSN : 1.9000 (+1.60%)
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027

Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent...

ONCY : 1.2995 (+1.52%)
ONC.TO : 1.66 (-0.60%)
EPZM : 1.4900 (unch)
AXSM : 48.36 (+8.04%)
DTIL : 1.6500 (+7.84%)
NRSN : 1.9000 (+1.60%)
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027

/PRNewswire/ -- Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent treatment. Factors...

ONC.TO : 1.66 (-0.60%)
ONCY : 1.2995 (+1.52%)
EPZM : 1.4900 (unch)
AXSM : 48.36 (+8.04%)
DTIL : 1.6500 (+7.84%)
NRSN : 1.9000 (+1.60%)
NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

NRSN : 1.9000 (+1.60%)
NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

NRSN : 1.9000 (+1.60%)
Why Is NeuroSense Therapeutics (NRSN) Stock Up 300% Today?

Big news from the FDA has this small pharma stock surging

NRSN : 1.9000 (+1.60%)

Business Summary

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company. It focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, such as ALS, Alzheimer's and Parkinson's disease. NeuroSense Therapeutics Ltd. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 2.0567
2nd Resistance Point 1.9933
1st Resistance Point 1.9467
Last Price 1.9000
1st Support Level 1.8367
2nd Support Level 1.7733
3rd Support Level 1.7267

See More

52-Week High 8.1800
Fibonacci 61.8% 5.5251
Fibonacci 50% 4.7050
Fibonacci 38.2% 3.8849
Last Price 1.9000
52-Week Low 1.2300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar